Literature DB >> 16633110

Progression to cirrhosis in Latinos with chronic hepatitis C: differences in Puerto Ricans with and without human immunodeficiency virus coinfection and along gender.

Maribel Rodríguez-Torres1, Carlos F Ríos-Bedoya, José Rodríguez-Orengo, Alberto Fernández-Carbia, Acisclo M Marxuach-Cuétara, Abimael López-Torres, Rosa Salgado-Mercado, Norbert Bräu.   

Abstract

BACKGROUND: Hepatitis C virus (HCV) infection is prevalent in Latinos. There is some evidence that progression to cirrhosis is more rapid. END POINTS: To calculate time of cirrhosis from time of HCV infection in a large Latino population. Other end points were to assess variables that predict cirrhosis and the effect of gender, alcohol, and human immunodeficiency virus (HIV) infection status on time to cirrhosis.
METHODS: Four hundred sixty-nine Latino patients evaluated at a referral center in Puerto Rico were included. Several demographic parameters, such as risk factors, estimated duration of HCV infection, alcohol use, HIV status, and findings from the usual HCV and HIV laboratory tests were noted. All patients had liver biopsy specimens assessed by Ishak score.
RESULTS: Monoinfected and coinfected latinos have a median cumulative risk/hazard for cirrhosis of 42.0 vs. 32.0 years after infection (P = 0.0016). The median age of cirrhotic patients is 53.0 years in monoinfections and 42.0 years in coinfection. Among coinfected patients there is no gender-associated difference in time to onset of cirrhosis (P = 0.785). Among monoinfected patients, males have a shorter median risk/hazard to cirrhosis than females (11.0-year difference; P = 0.05) and have a shorter time until onset of cirrhosis by fibrosis progression rate (FPR) (33.33 vs. 41.66 years; P = 0.021). There is no difference between male patients with regard to HIV status (P = 0.199). Alcohol use is significant in monoinfected males (59.2 g/day) vs. females (11.4 g/day; P = 0.001). Variables that predict cirrhosis are male sex, age, and Ishak grade in monoinfected patients and alanine aminotransferase value in coinfected patients.
CONCLUSIONS: Puerto Ricans with HCV have a median risk/hazard time to cirrhosis at younger age than other populations. Males who are HIV/HCV-coinfected have the same median risk/hazard and time to cirrhosis than those monoinfected with HCV. Special attention for early diagnosis and treatment is mandatory.

Entities:  

Mesh:

Year:  2006        PMID: 16633110     DOI: 10.1097/01.mcg.0000210105.66994.dc

Source DB:  PubMed          Journal:  J Clin Gastroenterol        ISSN: 0192-0790            Impact factor:   3.062


  11 in total

Review 1.  Sex differences in immune responses to infectious diseases.

Authors:  Julia Fischer; Norma Jung; Nirmal Robinson; Clara Lehmann
Journal:  Infection       Date:  2015-05-09       Impact factor: 3.553

2.  Predicting the probable outcome of treatment in HCV patients.

Authors:  Udayakumar Navaneethan; Nyingi Kemmer; Guy W Neff
Journal:  Therap Adv Gastroenterol       Date:  2009-09       Impact factor: 4.409

Review 3.  Hepatitis C virus (HCV) disease progression in people who inject drugs (PWID): A systematic review and meta-analysis.

Authors:  Daniel J Smith; Joan Combellick; Ashly E Jordan; Holly Hagan
Journal:  Int J Drug Policy       Date:  2015-07-26

4.  Factors influencing liver fibrosis and necroinflammation in HIV/HCV coinfection and HCV monoinfection.

Authors:  C Sagnelli; C Uberti-Foppa; G Pasquale; S De Pascalis; N Coppola; L Albarello; C Doglioni; A Lazzarin; E Sagnelli
Journal:  Infection       Date:  2013-07-10       Impact factor: 3.553

5.  Sex influences immune responses to viruses, and efficacy of prophylaxis and treatments for viral diseases.

Authors:  Sabra L Klein
Journal:  Bioessays       Date:  2012-09-26       Impact factor: 4.345

6.  SNPs in the promoter region of the osteopontin gene as a possible host factor for sex difference in hepatocellular carcinoma development in patients with HCV.

Authors:  Kazuhiro Hamaoka; Sumiko Nagoshi; Kayoko Sugawara; Kayoko Naiki; Yoshihito Uchida; Mie Inao; Nobuaki Nakayama; Kenji Fujiwara; Satoshi Mochida
Journal:  Hepatol Int       Date:  2012-10-06       Impact factor: 6.047

7.  Gender differences in clinical, immunological, and virological outcomes in highly active antiretroviral-treated HIV-HCV coinfected patients.

Authors:  Joel Emery; Neora Pick; Edward J Mills; Curtis L Cooper
Journal:  Patient Prefer Adherence       Date:  2010-05-13       Impact factor: 2.711

8.  Chronic Hepatitis C: Treatment, Complications, and Long-term Outcomes in a Population of Latino Veterans.

Authors:  Amarilys Santiago-Rolón; Dagmary Purcell; Nicole Grigg; Doris H Toro
Journal:  P R Health Sci J       Date:  2016-03       Impact factor: 0.705

Review 9.  Management of hepatitis C virus infection in HIV/HCV co-infected patients: clinical review.

Authors:  Ashwani-K Singal; Bhupinderjit S Anand
Journal:  World J Gastroenterol       Date:  2009-08-14       Impact factor: 5.742

10.  Features of hepatocellular carcinoma in Hispanics differ from African Americans and non-Hispanic Whites.

Authors:  Neeta K Venepalli; Mary V Modayil; Stephanie A Berg; Tad D Nair; Mayur Parepally; Priyanka Rajaram; Ron C Gaba; James T Bui; Yue Huang; Scott J Cotler
Journal:  World J Hepatol       Date:  2017-03-08
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.